CG Stock Recent News

Jeff Currie, Carlyle chief strategy officer of energy pathways, joins CNBC's 'Squawk on the Street' to discuss outlooks on energy.

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--StandardAero, Inc. (NYSE: SARO) (“StandardAero” or the “Company”) announced today the pricing of its underwritten public offering by two of its stockholders (the “Selling Stockholders”), affiliates of The Carlyle Group Inc. and GIC, of an aggregate of 30,000,000 shares of the Company's common stock, par value $0.01 per share (“Common Stock”), at a price to the public of $28.00 per share. The Selling Stockholders will receive all of the net proceeds from this.

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (“we,” “us,” “our,” “CCIF” or the “Fund”) (NYSE: CCIF) today announced its financial results for its second quarter ending March 31, 2025. The full detailed presentation of the Fund's second quarter 2025 financial results can be viewed on the Fund's website (carlylecreditincomefund.com/investor-dashboard).

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--StandardAero, Inc. (NYSE: SARO) (“StandardAero” or the “Company”) announced today that two of its stockholders (the “Selling Stockholders”), affiliates of The Carlyle Group Inc. and GIC, intend to offer for sale in an underwritten secondary offering an aggregate of 30,000,000 shares of the Company's common stock, par value $0.01 per share (the “Common Stock”), pursuant to the Company's shelf registration statement on Form S-1 filed with the Securities and Exc.

Establishes nitinol input tube operation to support premium, implant-grade tubing initiative and strengthen supply chain resilience NASHUA, N.H. , May 19, 2025 /PRNewswire/ -- Resonetics® announced today that it has acquired the nitinol gun drilling operations and related assets of Medical Component Specialists' (MCS) New Boston, NH facility.

SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instructions for stockholders to tender their shares into the offer. Updated Instructions for Stockholders: Contr.

Shares of bluebird bio Inc (NASDAQ:BLUE) surged 50% on Wednesday after the gene therapy developer announced an amended acquisition agreement with private equity firms Carlyle and SK Capital, offering shareholders a higher upfront cash payout. The revised deal includes a $5 per share cash offer, replacing a previous bid that had offered $3 per share upfront and a contingent value right (CVR) of $6.84 per share, payable if certain sales milestones were met.

Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) o.

Although the revenue and EPS for Carlyle (CG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.